Better cancer trials could be around the corner
21 Mar 2024
Clinical Study
COLD SPRING HARBOR, N.Y., March 21, 2024 /PRNewswire/ -- Cold Spring Harbor Laboratory Associate Professor and Cancer Center member Tobias Janowitz led a COVID-19 clinical trial with Northwell Health in 2021. When he and Clinical Fellow Hassal Lee reviewed the data, a surprising trend emerged. "The patient roster was very diverse," Janowitz explains. "We'd made no deliberate effort toward that other than conducting the trial remotely."
Continue Reading
Preview
Source: PRNewswire
Research suggests reducing patient travel requirements could lead to more diverse clinical trials. CSHL scientists’ new approach could help clinics identify more accessible locations and expand patient recruitment efforts. Image: © Paolese - stock.adobe.com
When it comes to cancer trials, many variables impact patient participation. One measurable factor is distance. On average, people are less likely to sign up for trials more than 30 minutes away. Karen Winkfield, Executive Director of the Meharry-Vanderbilt Alliance and member of the National Cancer Advisory Board, says:
"The biggest reason patients don't enroll is they're not asked. They aren't asked because there may not be clinical trials close to them."
Now, Janowitz and Lee have developed a new approach that may help clinics recruit patients from more communities. Using data from the U.S. Census Bureau, National Trial Registry, and other publicly funded organizations, the team created population maps for areas around highly active cancer trial sites. They found that high-volume sites are often in affluent neighborhoods with less diverse populations.
"Clinical trials should be accessible to all," Janowitz says. "Currently, 78 sites host about 94% of all U.S. cancer trials. We offer a new approach for these and other sites to use available data in designing more equitable clinical trials."
With their new tool, the team analyzed the sites' neighboring areas. They then identified nearby hospitals serving more diverse communities. Collaborating with these potential satellite sites could help expand patient recruitment efforts.
"For example, if you wanted to diversify the population for a clinical trial, you could use our tool to generate maps with whatever demographics you want," Lee explains. "It's transferable to any U.S. area as long as you have Census data."
Janowitz and his team are now working to expand their analysis to other population segments and trials unrelated to cancer. They hope their new approach will help streamline clinical trials. Winkfield, who co-authored the study, says:
"We can do a much better job of providing access to clinical trials in the communities where it matters most. If we're able to use this tool to make real collaborations with community health centers and hospitals that are interested, this could be a game changer."
The next step is to measure potential real-world impact. Janowitz and Lee suggest applying their approach to design new cancer trials. If they're right, the trials will be more readily available to all.
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,000 people including 600 scientists, students and technicians. For more information, visit www.cshl.edu
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.